Shares of Viking Therapeutics VKTX rose about 36% on Tuesday after the company announced positive data from a maintenance dosing study evaluating its lead obesity candidate, VK2735. Results showed that participants preserved most of their weight loss from the induction phase even when dosing frequency was materially reduced. VKTX Stock's Performance Year to date, the company's shares have gained 16% compared with the industry's 7% growth.Zacks Investment Research Image Source: Zacks Investment Research Viking's Maintenance Study Used a Two-Phase Dosing Design The maintenance study was designed to examine whether weight loss achieved with weekly VK2735 treatment could be sustained after reducing the frequency of dosing.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。